(2022-06-10 | NDAQ:GTBP) GT Biopharma Presents Preclinical Data Demonstrating Second-Generation CD19 Targeting Tri-Specific Killer Engager (TriKE®) Driving Robust NK Cell Function Against B Cell Malignancies at EHA 2022 Congress
Ongoing experiments will evaluate the functionality and efficacy of GTB-7550 in vivoFuture studies will also involve assessments of GTB-7550 TriKE efficacy.
GT Biopharma (GTBP) Reports Preclinical Data Demonstrating Second-Generation CD19 Targeting Tri-Specific Killer Engager Driving Robust NK Cell Function Against B Cell Malignancies streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.